Clinico-Hematological and cytogenetic spectrum of adult myelodysplastic syndrome: The first retrospective cross-sectional study in Iranian patients
Background Myelodysplastic syndrome (MDS), a heterogeneous group of hematopoietic
malignancy, has been shown to present different cytogenetic abnormalities, risk factors, and …
malignancy, has been shown to present different cytogenetic abnormalities, risk factors, and …
Cytogenetic profile and risk of transformation to acute myeloid leukemia (AML) in Indonesian patients with myelodysplastic syndrome (MDS): a pilot study
N Sutandyo, AS Kosasih, RM Sari, L Setiawan… - …, 2024 - f1000research.com
Background Cytogenetics is a fundamental examination in the course and management of
myelodysplastic syndrome (MDS) since it is widely used as a diagnostic and prognostic …
myelodysplastic syndrome (MDS) since it is widely used as a diagnostic and prognostic …
De Novo Philadelphia Chromosome (BCR/ABL1) Positive Myelodysplastic Syndrome: Is it a Distinct Molecular and Clinical Entity?
D Katalinic - Indian Journal of Hematology and Blood Transfusion, 2018 - Springer
To the Editor, Myelodysplastic syndromes (MDS) are a heterogenous group of clonal steam
cell disorders characterized by dysplastic changes of bone marrow and blood cells …
cell disorders characterized by dysplastic changes of bone marrow and blood cells …
[HTML][HTML] Clinical effect of decitabine in the treatment of myelodysplastic syndrome and influencing factors
T Liu, J Wang, C Li, L Jia - Pakistan Journal of Medical Sciences, 2020 - ncbi.nlm.nih.gov
Objective: To analyze the effect of decitabine combined with conventional chemotherapy on
myelodysplastic syndrome (MDS) and its influencing factors. Methods: Eighty patients with …
myelodysplastic syndrome (MDS) and its influencing factors. Methods: Eighty patients with …
Philadelphia translocation in MDS: a case report and a brief review of the literature looking at its prevalence, disease progression, and treatment options
LR Chelapareddy, S Sen - Case Reports in Hematology, 2018 - Wiley Online Library
Myelodysplastic syndrome (MDS) is a group of clonal disorders characterized by ineffective
and dysplastic hematopoiesis in the bone marrow with variable risk of progression to …
and dysplastic hematopoiesis in the bone marrow with variable risk of progression to …
BCR/ABL analysis in myelodysplastic syndromes
OK Ghale-sardi, MA JalaliFar, E Khodadi… - Comparative Clinical …, 2018 - Springer
Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid disorders
commonly occurring in older patients. Several genetic abnormalities have been observed in …
commonly occurring in older patients. Several genetic abnormalities have been observed in …
好中球減少と貧血にて発症しimatinib mesylate が著効したmajor BCR-ABL1 陽性骨髄異形成症候群
土井章一， 田代裕介， 吉永則良， 岸本渉， 濵田常義… - 臨床血液, 2020 - jstage.jst.go.jp
抄録 81 歳女性が好中球減少と貧血で紹介された. 骨髄で好中球脱顆粒, 分離多核巨核球,
巨赤芽球変化を認めた. 骨髄芽球は 2.6% で, 形態的診断は, 骨髄異形成症候群 (MDS-MLD) …
巨赤芽球変化を認めた. 骨髄芽球は 2.6% で, 形態的診断は, 骨髄異形成症候群 (MDS-MLD) …